JPH10506791A - 治療用送達系としての微生物 - Google Patents

治療用送達系としての微生物

Info

Publication number
JPH10506791A
JPH10506791A JP8512318A JP51231896A JPH10506791A JP H10506791 A JPH10506791 A JP H10506791A JP 8512318 A JP8512318 A JP 8512318A JP 51231896 A JP51231896 A JP 51231896A JP H10506791 A JPH10506791 A JP H10506791A
Authority
JP
Japan
Prior art keywords
protein
lactobacillus
bacillus
bacillus subtilis
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8512318A
Other languages
English (en)
Japanese (ja)
Inventor
アルド タグリアブエ,
デイアナ ボラシ,
パオラ ボツス,
ジヨバンニ マツキア,
ジヨバンニ マウリツツイ,
ステフアノ ポルツイオ,
パオロ ルツジーロ,
Original Assignee
ドンペ・ソチエタ・ペル・アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドンペ・ソチエタ・ペル・アチオニ filed Critical ドンペ・ソチエタ・ペル・アチオニ
Publication of JPH10506791A publication Critical patent/JPH10506791A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP8512318A 1994-10-05 1995-10-04 治療用送達系としての微生物 Pending JPH10506791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT94A002025 1994-10-05
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
PCT/EP1995/003921 WO1996011277A1 (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems

Publications (1)

Publication Number Publication Date
JPH10506791A true JPH10506791A (ja) 1998-07-07

Family

ID=11369649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8512318A Pending JPH10506791A (ja) 1994-10-05 1995-10-04 治療用送達系としての微生物

Country Status (6)

Country Link
EP (1) EP0784689A1 (it)
JP (1) JPH10506791A (it)
AU (1) AU3745395A (it)
CA (1) CA2201721A1 (it)
IT (1) IT1270123B (it)
WO (1) WO1996011277A1 (it)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528392A (ja) * 1998-10-20 2002-09-03 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
JP2003504025A (ja) * 1999-07-05 2003-02-04 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー トレフォイルペプチドの送達
WO2006028214A1 (ja) 2004-09-10 2006-03-16 Asahi Glass Company, Limited 経口投与ワクチン
JP2008067708A (ja) * 1995-10-20 2008-03-27 Actogenix Nv 生物学的に活性のあるポリペプチドのデリバリー
JP2013517256A (ja) * 2010-01-14 2013-05-16 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) 炎症性腸疾患(ibd)及び過敏性腸症候群(ibs)の予防及び治療のための組換体プロバイオティック細菌

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AU749695B2 (en) 1997-09-10 2002-07-04 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
FR2791998B1 (fr) * 1999-04-07 2001-06-08 Agronomique Inst Nat Rech Lactocoques modifies exprimant une catalase et leurs utilisations
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
ATE381351T1 (de) * 2000-07-27 2008-01-15 Univ Pennsylvania Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
CA2342040C (en) 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2003063786A2 (en) * 2002-01-31 2003-08-07 Symbigene, Inc. Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
WO2004007695A2 (en) * 2002-03-08 2004-01-22 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
EP1513545B1 (en) * 2002-06-19 2008-03-19 Actogenix N.V. Methods and means to promote gut absorption
EP1590443A4 (en) * 2003-01-29 2009-01-07 Osel Inc SURFACE EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN BACTERIA
EP1786445B1 (en) 2004-08-25 2011-06-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Live microbial microbicides
US7456011B2 (en) 2005-01-12 2008-11-25 Osel, Inc. Modified cyanovirin-n polypeptide
EP1957100B1 (en) 2005-11-29 2016-07-13 Intrexon Actobiotics NV Induction of mucosal tolerance to antigens
BRPI0711119A2 (pt) * 2006-05-02 2011-08-30 Actogenix Nv administração microbiana de peptìdeos intestinais associados à obesidade
AU2008204442B2 (en) 2007-01-12 2013-03-14 Intrexon Actobiotics Nv Lactococcus promoters and uses thereof
EP2125010B1 (en) 2007-01-25 2014-06-04 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
JP2012504116A (ja) 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ 粘膜での微生物のコロニー形成の低減
DK2424972T3 (da) 2009-04-30 2013-10-14 Actogenix Nv Kryobeskyttende midler til frysetørring af mælkesyrebakterier
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
FR2960001A1 (fr) * 2010-05-12 2011-11-18 Univ Rennes Vecteur recombinant pour la production et la secretion de sequences d'acides amines d'interet par les bacteries propioniques et ses applications
US9476056B2 (en) 2010-05-12 2016-10-25 Universite De Rennes 1 Recombinant vector for producing and secreting peptide or protein of interest by propionibacteria and applications thereof
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
CN101921725B (zh) * 2010-07-27 2013-06-05 浙江大学 一种口服免疫阻断鸡生长抑素作用的转化子及其应用
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
HUE038336T2 (hu) 2011-09-23 2018-10-29 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
AU2013299605A1 (en) 2012-08-07 2015-03-26 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
US10064797B2 (en) 2014-06-17 2018-09-04 TopGeniX, Inc. Topical formulations for UV protection
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
HRP20240085T1 (hr) 2019-03-04 2024-03-29 Aurealis Therapeutics AG Prokariotski ekspresijski sustav indukciran kloridom

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1321962C (en) * 1985-03-20 1993-09-07 Aizo Matsushiro Dental caries preventive preparations and method for preparing said preparations

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008067708A (ja) * 1995-10-20 2008-03-27 Actogenix Nv 生物学的に活性のあるポリペプチドのデリバリー
JP2002528392A (ja) * 1998-10-20 2002-09-03 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
JP2010222364A (ja) * 1998-10-20 2010-10-07 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
JP2003504025A (ja) * 1999-07-05 2003-02-04 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー トレフォイルペプチドの送達
JP4644401B2 (ja) * 1999-07-05 2011-03-02 アクトジェニックス・エヌブイ トレフォイルペプチドの送達
WO2006028214A1 (ja) 2004-09-10 2006-03-16 Asahi Glass Company, Limited 経口投与ワクチン
US8282936B2 (en) 2004-09-10 2012-10-09 Asahi Glass Company, Ltd. Human papillomavirus vaccine for oral administration
JP2013517256A (ja) * 2010-01-14 2013-05-16 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) 炎症性腸疾患(ibd)及び過敏性腸症候群(ibs)の予防及び治療のための組換体プロバイオティック細菌

Also Published As

Publication number Publication date
ITMI942025A1 (it) 1996-04-05
AU3745395A (en) 1996-05-02
IT1270123B (it) 1997-04-28
EP0784689A1 (en) 1997-07-23
WO1996011277A1 (en) 1996-04-18
CA2201721A1 (en) 1996-04-18
ITMI942025A0 (it) 1994-10-05

Similar Documents

Publication Publication Date Title
JPH10506791A (ja) 治療用送達系としての微生物
ES2351349T3 (es) Liberación de péptidos trébol.
EP2344626B1 (en) Reduced colonization of microbes at the mucosa
EP3124614B1 (en) Lactococcus promoters and uses thereof
US20040106564A1 (en) Use of slpi for treating chronic inflammatory intestinal diseases
US5922583A (en) Methods for production of recombinant plasmids
JP2007503845A (ja) 細菌における生物学的に活性なタンパク質の表面発現
US20120183503A1 (en) Lactobacillus and streptococcus promoters and uses thereof
AU704594B2 (en) Production of recombinant peptides as natural hydrophobic peptide analogues
Wells et al. Progress in the development of mucosal vaccines based on Lactococcus lactis
JP2001526533A (ja) λ様プロモーターを有する遺伝子の誘導性発現のための調節系
AU2003249855B2 (en) Cell wall mutants for delivery of biologically active compounds
JP3288373B2 (ja) 安定および生体活性改変ソマトトロピン類
MXPA06000264A (es) Expresion recombinante de cisteina proteasa de streptococcus pyogenes y composiciones inmunogenicas de las mismas.
AU2002357406B2 (en) Defective entities and uses therefor
WO2009020577A2 (en) Innovative formulation for oral insulin delivery
NZ533920A (en) Defective entities and uses therefor